News

Orenitram (treprostinil tablets) reduced clinical worsening and slowed disease progression in people with pulmonary arterial hypertension (PAH) who had recently begun treatment with an alternative approved therapy, a Phase 3 clinical trial has found. Trial findings were reported in the study, “Combination Therapy with Oral Treprostinil for Pulmonary…

AI Therapeutics is seeking to advance the development of its candidate treatment LAM-001 for patients with lymphangioleiomyomatosis (LAM) and pulmonary arterial hypertension (PAH), two rare lung disorders. Specifically, the company is looking for a collaborator with commercial expertise to advance LAM-001 in a registrational trial for LAM…

An international consensus is lacking about what constitutes pulmonary hypertension (PH) in newborns, according to a review study, which recommends the use of standardized criteria to define the disease in these patients. The systematic review, “Variation in the definition of pulmonary hypertension and clinical indications for the use…

Acceleron Pharma and Fulcrum Therapeutics are working together to discover small molecules that can be used to treat pulmonary diseases, including pulmonary hypertension (PH). Under this collaboration, Acceleron will be able to access Fulcrum’s proprietary product engine and target identification platform, in order to identify small molecules…

Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…

Bellerophon Therapeutics’ vasodilator INOpulse increased physical activity and improved quality of life in people with interstitial lung disease (PH-ILD) who are at risk of pulmonary hypertension, top-line results from a Phase 2/3 clinical trial show. These results are from the second group of patients taking part in…

Melatonin, a natural hormone involved in sleep and believed to protect against cardiovascular diseases, may help to relieve the signs and symptoms of pulmonary arterial hypertension (PAH), an early study in mice reports. In mice, melatonin protected lung blood vessels from damage, and inactivated proteins responsible for setting…

Tikosyn (dofetilide), a medicine approved by the U.S. Food and Drug Administration (FDA) to treat heart arrhythmias, may be used to treat pulmonary arterial hypertension (PAH), a recent study suggests. The findings warrant further investigation into the therapy’s potential positive effects for patients with PAH,…

Bioelectronic medicine is a promising new therapeutic approach to treat pulmonary arterial hypertension (PAH), according to a recent review study. The review, “Pulmonary arterial hypertension: the case for a bioelectronic treatment,” was published in the journal Bioelectronic Medicine. Current treatments for PAH include medications that interfere with…

Pulmonary hypertension (PH) is highly prevalent and linked to increased mortality and hospitalization among patients who underwent minimally invasive transcatheter mitral valve repair — the repair of the valve placed between the two chambers in the left side of the heart — according to a retrospective study. The study,…

With so much recent publicity surrounding gene therapy, it’s no surprise that the topic was a major focus of the recent 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit. From diagnosis and clinical trial design to manufacturing, pricing strategies, and ethical concerns, gene therapy — both its high…

TriAxia Health is partnering with three academic medical centers to build a large database aiming for a better understanding of rare pulmonary diseases, beginning with pulmonary arterial hypertension (PAH). To be meaningful, medical research often requires very large quantities of data. Bigger datasets give a study greater statistical…